Pular para o conteúdo principal
Ranking Invest

ARCT - Arcturus Therapeutics Holdings Inc.

Segmento: HealthcareArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Análise Ranking Invest

Valuation estimado
$ 50.65 Mi
Valor de Mercado
$ 418.53 Mi
Sobrepreço (AV)+726.4%
IVR
0.12A companhia vale 0,12 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.34O valuation alternativo equivale a -34% do valor de mercado da companhia.
MLL
-0.34O lucro líquido dos controladores em 16 trimestres equivale a -34% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 171.81 Mi

Dívida Líquida

-$ 191.48 Mi

L4T

-$ 93.28 Mi

MM4T

-648.64%

Indicadores Básicos

ROE

-54.29%

Índices de Previsibilidade

Receita Líquida

F0.45

Lucro

D0.99

Margem

F2.01

Índices de Tendência

Receita Líquida

E-6.87

Lucro

E-2.31

Margem

F-6.14

Índices de Endividamento

DIV/PAT

-1.11

DIV/L4T

2.05

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.